Overview and Scope
Acute ischemic stroke drugs refer to treatment medications for a medical emergency that occurs when blood flow to the brain is interrupted, typically due to a blood clot. These drugs aim to restore blood flow to the affected part of the brain and minimize brain damage.
Sizing and Forecast
The acute ischemic stroke drugs market size has grown strongly in recent years. It will grow from $13.01 billion in 2023 to $13.66 billion in 2024 at a compound annual growth rate (CAGR) of 5.0%. The growth in the historic period can be attributed to increasing incidence of stroke, government initiatives and healthcare policies, increased awareness and education, strategic collaborations and partnerships, aging population.
The acute ischemic stroke drugs market size is expected to see strong growth in the next few years. It will grow to $16.87 billion in 2028 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to emerging therapies and drug pipeline, precision medicine and personalized therapies, global healthcare infrastructure development, increasing healthcare expenditure, telemedicine and remote patient monitoring. Major trends in the forecast period include advancements in thrombolytic therapies, neuroprotective agents development, personalized medicine and biomarker research, telemedicine and remote monitoring, collaborations and strategic partnerships.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/acute-ischemic-stroke-drugs-global-market-report
Segmentation & Regional Insights
The acute ischemic stroke drugs market covered in this report is segmented –
1) By Type: Tablet, Capsule, Other Types
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Hospitals, Diagnostic Centers, Other Applications
North America was the largest region in the acute ischemic stroke drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global acute ischemic stroke drugs market report during the forecast period. The regions covered in the acute ischemic stroke drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=10049&type=smp
Major Driver Impacting Market Growth
The rise in the prevalence of chronic diseases is anticipated to propel the growth of the acute ischemic stroke drug market in the coming years. Chronic diseases, also known as non-communicable diseases, refer to conditions that endure for a year or longer and necessitate continuing medical care, restrict everyday activities, or both. The primary causes of death and disability are chronic illnesses such as heart disease, cancer, and diabetes. Acute ischemic stroke drugs are primarily used in chronic diseases to reduce the chances of clot formation and strokes and restore blood flow to the brain. For instance, in September 2022, according to the reports shared by the World Health Organization (WHO), a Switzerland-based health agency, due to chronic diseases, it is estimated 41 million people die each year, which is equivalent to 74% of all deaths globally, and 17 million individuals die before the age of 70 from chronic diseases. By 2025, an estimated 164 million Americans, or nearly 49% of the population, would be living with chronic illnesses. Therefore, the rise in the prevalence of chronic diseases is driving the growth of the acute ischemic stroke drug market.
Key Industry Players
Major companies operating in the acute ischemic stroke drugs market report are F. Hoffmann-La Roche AG, C.H. Boehringer Sohn AG & Co. KG, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, AstraZeneca PLC, ZZ Biotech LLC, NoNO Inc., Biogen Inc., Athersys Inc., Bayer AG, Sanofi S.A., Pfizer Inc., DiaMedica Therapeutics, Lumosa Therapeutics Co. Ltd., Johnson & Johnson, Acticor Biotech, Meridigen Biotech Co., Prolong Pharmaceuticals LLC, Nanjing Yoko Biomedical Co. Ltd., TrueBinding Inc., GNT Pharma Co. Ltd., aptaTargets SL, NuvOX Pharma, Simcere Pharmaceutical Co. Ltd., Genentech Inc., Pharming Technologies B.V., SanBio BV, Revalesio Corporation, Stemedica Cell Technologies Inc., CorInnova Incorporated, Phagenesis, Aidoc Medical
The acute ischemic stroke drugs market report table of contents includes:
1. Executive Summary
2. Acute Ischemic Stroke Drugs Market Characteristics
3. Acute Ischemic Stroke Drugs Market Trends And Strategies
4. Acute Ischemic Stroke Drugs Market – Macro Economic Scenario
5. Global Acute Ischemic Stroke Drugs Market Size and Growth
.
.
.
31. Global Acute Ischemic Stroke Drugs Market Competitive Benchmarking
32. Global Acute Ischemic Stroke Drugs Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Acute Ischemic Stroke Drugs Market
34. Acute Ischemic Stroke Drugs Market Future Outlook and Potential Analysis
35. Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
